Navigation Links
Identified as responsible for breast and ovarian hereditary cancer 3 mutations at BRCA1 gene
Date:4/18/2013

Researchers of the hereditary cancer research group at the Bellvitge Biomedical Research Institute (IDIBELL) and the Catalan Institute of Oncology (ICO) conducted a functional and structural study of seven missense variants of the BRCA1 gene concluding that three of these variants are pathogenic, linked to the risk of suffering breast or ovarian cancer. The study has been published in the journal PLoS One

The classification of these three variants will improve genetic counseling of patients and families who have these mutations and will serve to personalize the treatment.

Mutations in BRCA1 gene

Mutations in BRCA1 confer a high risk of developing breast or ovarian cancer. A woman carrying a mutation in this gene has a risk of developing breast cancer between 40% and 90% and of developing ovarian cancer between 20% and 70%.

According to the researcher Conxi Lzaro, "now we know a lot of genetic alterations in BRCA1 that are clearly pathogenic alterations, neutral alterations and sequence polymorphisms, but genetic diagnostic studies also identify changes in the DNA sequence which we don't know its biological significance."

For the researcher, finding out the biological consequences of these missense variants is "a technological challenge, not only in breast cancer but in the field of genetic diagnostics in general."

Study of seven missense variants

The study analyzes seven BRCA1 gene variants from a structural and functional standpoint. Structural analysis is a theoric-computational analysis and compares the three-dimensional structure of normal protein with the analyzed changes. The researchers conclude that three of the seven variants analyzed modify the structure of the protein.

"In the functional study," said the researcher, "we analyzed in vitro one of the key functions of BRCA1: regulation of transcription. The analysis involves the generation of mutants of all var
'/>"/>

Contact: Arantxa Mena
comunicacio@idibell.cat
34-932-607-129
IDIBELL-Bellvitge Biomedical Research Institute
Source:Eurekalert

Page: 1 2

Related biology news :

1. First genetic factor in prostate cancer prognosis identified
2. US company identified as manufacture of lead paint in Africa
3. Potential early indicator of kidney injury identified
4. 4 dinosaur egg species identified in Lleida
5. March of Dimes awards $250,000 to researcher who identified heart disease genes
6. Mechanisms regulating inflammation associated with type 2 diabetes, cancer identified
7. New type of gene that regulates tumor suppressor PTEN identified
8. Molecular basis identified for tissue specific immune regulation in the eye and kidney
9. Newly identified natural protein blocks HIV, other deadly viruses
10. New genes for short-sightedness identified
11. Triple-negative breast cancer subtypes identified using microRNA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... of consumers are willing to pay a premium for ... they,re getting what the label claims is another matter. ... a new way to make sure farms are labelling ... Journal of Agricultural and Food Chemistry , could ... Bavarian Health and Food Safety Authority and the Wuerzburg ...
(Date:8/27/2014)... studies have shown that excessive iron is ... disease. Previous studies from Chunyan Guo and ... have shown that baicalin prevented iron accumulation ... transporter 1 expression, and increased ferroportin 1 ... Parkinson,s disease rats. However, the relationship between ...
(Date:8/27/2014)... are greedy bird-brains, University of Warwick research finds ... they make risky decisions, new research has shown. , ... of Warwick,s Department of Psychology, conducted tests that found ... likely to gamble for high-value than low-value rewards. , ... that the test results show the important role that ...
Breaking Biology News(10 mins):Gamblers are greedy bird-brains, University of Warwick research finds 2
... and the U.S.A., the scientists have shown how cutting-edge ... of active proteins in cell organelles at a particular ... use proteins. The work is published in the journal ... cities. They contain all the necessary parts that allow ...
... the use of liquid crystalline polymers (LCP) as a ... sought-after lab-on-a-chip technology. , University of Alberta researchers, collaborating ... Phillips Research Laboratories in the Netherlands, have shown that ... glass backing, can be fabricated and patterned on a ...
... of dengue fever wax and wane over a period ... why. With the incidence and range of the potentially ... these epidemics has never been more important. , A ... suggests that a brief period of cross-immunity conferred by ...
Cached Biology News:A catalogue of proteins 2Polymers show promise for lab-on-a-chip technology 2UGA study explains peaks and troughs of dengue epidemics 2UGA study explains peaks and troughs of dengue epidemics 3
(Date:8/27/2014)... , Aug. 27, 2014 Reportlinker.com announces ... in its catalogue: Global Chelating Agents ... About Chelating Agent A chelating agent ... bonds with metal ions, thereby forming a metal-ion ... metal-ions have on chemical processes, formulations, and the ...
(Date:8/27/2014)... 27, 2014  A novel biomarker for rheumatoid ... better identify early-stage disease, when treatment can often ... a new study in The Journal of Rheumatology. ... DGX ) and other institutions found that ... conventional antibody-serum testing, including rheumatoid factor (RF) and ...
(Date:8/27/2014)... LONDON , Aug. 27, 2014 ... The Graphene Opportunity - A Rational ... Is Graphene The New Nanotech? A similar ... predictions of applications ranging from microelectronics to water ... today announced the availability of the Graphene Opportunity ...
(Date:8/27/2014)... -- Research and Markets  has announced the addition ... Industry Report 2014" report to their offering. ... Industry Report 2014 is a professional and in-depth study ... mass spectrometer industry. The report provides a ... and industry chain structure. The isotope ratio mass spectrometer ...
Breaking Biology Technology:Global Chelating Agents Market 2014-2018 2Global Chelating Agents Market 2014-2018 3Global Chelating Agents Market 2014-2018 4Novel Biomarker Detects Early Rheumatoid Arthritis Better than Conventional Methods Alone, According to Journal of Rheumatology Study 2Novel Biomarker Detects Early Rheumatoid Arthritis Better than Conventional Methods Alone, According to Journal of Rheumatology Study 3Novel Biomarker Detects Early Rheumatoid Arthritis Better than Conventional Methods Alone, According to Journal of Rheumatology Study 4The Graphene Opportunity - A Rational View 2The Graphene Opportunity - A Rational View 3The Graphene Opportunity - A Rational View 4Global Stable Isotope Ratio Mass Spectrometer Industry Report 2014 2
... /Xinhua-PRNewswire-FirstCall/ -- American Oriental,Bioengineering, Inc. (NYSE: AOB ... quarter 2008 financial results on Monday, November 10, ... hold a conference call at 8:00 am ET ... 2008 results. Listeners may access the,call by dialing ...
... 30 /PRNewswire-FirstCall/,-- Oridion Systems Ltd. (SWX: ORIDN) ... Foundation Health Plan, Inc., America,s largest,non-profit health ... in the world. The agreement is for ... sampling consumables (FilterLine(R))., With this agreement, ...
... ... Guidance of $0.90 - $1.10 for 2009 and $1.50 - $1.70 ... for 2010, PITTSBURGH, Oct. 30 ... months ended,Sept. 30, 2008., Financial Highlights, -- Adjusted diluted EPS of $0.23 and $0.52 ...
Cached Biology Technology:Oridion Signs Agreement With Major US Health Plan Provider for Microstream(R) Capnography 2Oridion Signs Agreement With Major US Health Plan Provider for Microstream(R) Capnography 3Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008 2Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008 3Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008 4Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008 5Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008 6Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008 7Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008 8Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008 9Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008 10Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008 11Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008 12Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008 13Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008 14
Request Info...
Request Info...
Detect and measure levels of mouse IgG2b antibody isotypes quickly and easily....
Detect and measure levels of mouse IgG3 antibody isotypes quickly and easily....
Biology Products: